

# **MRA 2022 Scientific Retreat**

March 9 - March 11, 2022, Washington, DC

## Wednesday, March 9

| 6:00-7:30pm    | Opening Reception Penn Avenue Terrace   |
|----------------|---|
| 4:00-8:00pm    | Retreat Registration open Foyer of Penn Avenue Terrace                                    |
| 11:45-5:30pm   | Melanoma Patients, Advocates & Foundations ForumJ.W. Marriott, Salon II & III             |
| 7:30am- 5:00pm | Grant Review Committee Meeting (by invitation)Milken Institute, 730 15th St NW, 2nd floor |

### Thursday, March 10

| 6:30am-6:00pm | Registration Foyer of Salon III & IV  |
|---------------|---|
| 7:00-8:15am   | General BreakfastSalon II   |
| 7:00-8:15am   | Young Investigators Breakfast (by invitation)   |
| 8:30-8:45am   | Opening Remarks Day 1Salon III & IV<br>Michael Kaplan, MRA President & CEO<br>Keith Tolley, Patient Advocate<br>J.B. Ward, Patient Advocate<br>Marc Hurlbert, MRA Chief Science Officer |
| 8:45-9:15am   | Lecture<br>Jason Luke, University of Pittsburgh – Integrating clinical and genomic observations to<br>advance combination therapies in melanoma   |
| 9:15-11:40am  | Session 1: Novel treatment strategies for melanoma<br>Chair: C. Daniela Robles-Espinoza, National Autonomous University of Mexico   |
| 9:15-9:40am   | <b>Rhoda Alani, Boston University:</b><br>The CoREST repressor complex as a mediator of phenotype switching and therapy<br>resistance in melanoma                                       |
| 9:40-10:05am  | Jiyue Zhu, Washington State University: Telomere homeostasis in melanoma  |
| 10:05-10:30am | Break   |
| 10:30-10:55am | <b>Thomas Graeber, University of California, Los Angeles:</b> Plasticity of extrachromosomal and intrachromosomal BRAF amplifications in overcoming targeted therapy dosage challenges  |
| 10:55-11:15am | Daniela De Zio, Danish Cancer Society Research Center & University of Copenhagen:<br>The tumor suppressor role of Ambra1 in melanoma  |
| 11:15-11:40am | Adam Hurlstone, University of Manchester: Fat uptake into and fat storage in melanoma cells promotes melanoma formation but are actionable targets                                      |

#### 11:40am-11:55am Transition to lunch 1. Acral + mucosal patient registry (salon H/J) 11. Mentoring / mentorship 2. Biomarkers 12. Metastasis and tumor dormancy 3. Brain metastasis and LMD 13. Microbiome 4. Clinical trials 14. Neoadjuvant & adjuvant therapy 5. Diversitv 15. Prevention 6. Early detection & diagnosis 16. Treatment – new targets & drug discovery 7. Genomics 17. Tumor microenvironment 8. Intralesional therapies 18. Vaccines 19. Uveal melanoma 9. irAE – understanding irAE 20. Women in melanoma research and care 10. Melanoma model systems 1:20-1:25pm Transition to general session room (Salon III & IV) 1:30-3:00pm Session 2: Next generation immunotherapies and addressing irAEs.....Salon III & IV Chair: Joan Levy, Melanoma Research Alliance David Gerber, UT Southwestern: Trouble in paradise? Immunotherapy selection, 1:30-1:55pm and toxicities 1:55-2:15pm Ken Hsu, University of Virginia: Functional reporters of T cell metabolism for immunotherapy applications 2:15-2:35pm Simon Heidegger, Munich Technical University: Tumor-derived extracellular vesicles as personalized anti-tumor agents in melanoma Michal Lotem, Hadassah Medical Organization: Spliced immune receptors for immune 2:35-3:00pm regulation and melanoma immunotherapy 3:00-3:30pm Break 3:30-4:30pm Session 3: Special Focus – Highlighting MRA Young Investigator Awardees Chair: Kim Blenman, Yale University 3:30-3:40pm Rachel Vogel, University of Minnesota: Effectiveness of a UVR-sensor wearable device intervention to improve sun behaviors and reduce sunburns in melanoma survivors Veronica Rotemberg, Memorial Sloan Kettering Cancer Center: Factors that influence 3:40-3:50pm automated melanoma detection 3:50-4:00pm Ed Stites, Salk Institute: Computational analyses of RAS/RAF pathway signaling 4:00-4:10pm Ashley Laughney, Joan & Sanford I. Weill Medical College of Cornell University: Single cell analyses reveal an unexpected link between epigenetic dysregulation and chromosomal instability in uveal melanoma progression 4:10-4:20pm **Russell Jenkins, Massachusetts General Hospital:** Targeting TBK1 to overcome resistance to cancer immunotherapy

| 4:25-4:30pm | <b>Closing Remarks Day 1</b><br>Rachel Fischer, MRA Senior Scientific Program and Registry Manager   |              |
|-------------|--|--------------|
| 4:45-6:15pm | Poster Session I: Features Dermatology Fellow, Young Investigator,<br>Pilot Awardees, and Sponsors<br>Light refreshments, all retreat attendees encouraged to attend | Salon I & II |

Dinner on Your Own: Explore DC, meet up with friends, or take it easy!

## Friday, March 11

| 6:30-10:00am  | Registration open Foyer of Salon III & IV  |
|---------------|--|
| 7:00-8:50am   | General BreakfastSalon II  |
| 7:20-8:50am   | Poster Session II: Features Young Investigator AwardeesSalon I & II  |
| 7:30-8:50am   | Industry Roundtable Breakfast (by invitation) Willard Intercontinental, Willard Room   |
| 9:00-9:05am   | Opening Remarks Day 2Salon III & IV  |
|               | Joan Levy, Senior Director, Special Scientific Projects  |
| 9:05-9:35am   | Lecture<br>Laurence Zitvogel, Institut Gustave Roussy: Impact of the intestinal microbiota on the clinical<br>efficacy of immune checkpoint blockade                             |
| 9:35-10:20am  | Session 4: Improving risk assessment & anti-tumor immunity in melanoma<br>Chair: Shaheen Khan, University of Texas Southwestern  |
| 9:35-9:55am   | Maria Wei, University of California, San Francisco: Applying artificial intelligence to melanoma screening and detection   |
| 9:55-10:20am  | <b>Leonard Zon, Harvard Medical School:</b> Craters on the melanoma surface serve as hubs for CD8+ T cells   |
| 10:20-10:40am | Break  |
| 10:40-11:30am | Session 5: Understanding therapeutic resistance<br>Chair: Roberto Tinoco, University of California Irvine  |
| 10:40-11:05am | <b>Roger Lo, University of California, Los Angeles:</b> Targeting adaptive immune resistance by degrading tumor cell-surface PD-L1 to promote anti-melanoma therapeutic efficacy |
| 11:05-11:30am | Jean-Christophe Marine, VIB: Charting dynamics & functional maps of the evolving melanoma ecosystem  |
|               |  |

| 11:30am-12:30pm | Panel Discussion: Treating melanoma in 2022: An evolving landscape<br>Moderator: Jonathan Simons (MRA Board Member)             |
|-----------------|---|
|                 | Panelists:  |
|                 | <ul> <li>Rodabe Amaria, University of Texas MD Anderson Cancer Center</li> <li>Michael Atkins, Georgetown University</li> </ul> |
|                 | Evan Lipson, Johns Hopkins University   |
|                 | Marlana Orloff, Thomas Jefferson University   |
| 12:30pm-12:45pm | Closing Remarks<br>Marc Hurlbert and Rachel Fischer   |
| 12:45-1:45 pm   | Lunch and DeparturesSalon II  |

# Melanoma Research Alliance

# **Melanoma Exchange** Patient and Advocate Forum

March 9

| 11:30-11:45am  | Registration & Check in*  |
|----------------|---|
| 11:45-1:00pm   | Networking Roundtables with Lunch*  |
| 1:00-1:10pm    | Welcome Remarks<br>Michael Kaplan – President & CEO, Melanoma Research Alliance   |
| 1:10-1:45pm    | <b>Biomarkers: Lighting the Way</b><br>From diagnosis to treatment selection, biomarker tests are increasingly being used to inform<br>the care we receive. Learn what exists and how they're used.<br><i>David Polsky, MD, PhD - New York University Langone Health</i>  |
| 1:45-2:45pm    | <b>One Step at a Time: A Melanoma Journey</b><br>While no two melanoma journeys are exactly alike, similarities exist. Get tips and insight as<br>this panel takes us through a hypothetical patient journey.<br>Danielle Bello, MD - Memorial Sloan Kettering Cancer Center<br>Hensin Tsao, MD, PhD - Massachusetts General Hospital<br>Rodabe Amaria, MD - The University of Texas MD Anderson Cancer Center  |
| 2:45-3:00pm    | Break   |
| 3:00-3:55pm    | <b>Step-by-Step: Living with Melanoma: A Panel Conversation</b><br>Hear from this diverse panel of people who have been impacted by melanoma.<br><i>Amy Jardon - Melanoma Advocate</i><br><i>J.B. Ward - Melanoma Advocate</i><br><i>Christine Garrison - Vice President, Melanoma Action Coalition</i><br><i>Cody Barnett - Director of Communications &amp; Patient Engagement, MRA</i>   |
| 3:55 - 4:30pm  | <b>On the Horizon: Emerging Therapies to Watch</b><br>The melanoma research landscape is advancing rapidly, with many clinical trials reporting<br>positive results. Learn how these results are being translated into the clinic.<br><i>Hussein Tawbi, MD, PhD - The University of Texas MD Anderson Cancer Center</i>   |
| 4:30 - 5:25 pm | <b>Staying on the Path: Prevention for the Melanoma Community</b><br>We all know the importance sun safety and prevention, but what does that really look like<br>for people in the melanoma community? Get your questions ready for this interactive panel<br>discussion.<br><i>Susan Swetter, MD - Stanford University</i><br><i>Rachel Vogel, PhD - University of Minnesota</i><br><i>Maria Wei, MD, PhD - University of California San Francisco</i><br><i>Tracy Callahan - President &amp; CEO, Polka Dot Mama Melanoma Foundation</i> |
| 5:25 - 5:30pm  | Closing & Wrap-up   |